Conclusion of a non-exclusive rebate agreement under Section 130a(8) of the German Social Code V for the active substance trastuzumab (exclusively 600 mg i.e.D.), ATC L01FD01, for the period 01/06/2026 - 31/05/2028

Summary

The tender concerns a non-exclusive rebate agreement for the active substance trastuzumab for the period 01/06/2026 to 31/05/2028. It is an open accession model in which DAK-Gesundheit intends to conclude contracts with as many interested pharmaceutical companies as possible. The bidder must submit the required documents by email for contract conclusion or later accession, and the exact requirements must be checked in the tender documents.